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Abstract: ANKH (human homolog of progressive ankylosis) regulates inorganic pyrophosphate (PPi) transport. Domi-
nant ANKH mutations were detected in at least five multiplex families with calcium pyrophosphate dihydrate crystal 
deposition disease (CPPPD). The objective of this study is to assess the functional consequences of one CPPDD-
associated ANKH mutation (E490) in chondrogenic ATDC5 cells. Stable ATDC5 transfectants bearing myc-tagged con-
structs of wild-type ANKH, mutant ANKH (E490) and neo controls were generated. Upon ITS (insulin, transferrin and 
selenium) induction, expression of chondrocyte markers including alkaline phosphatase activity in the various transfec-
tants was assessed. The ANKH E490- transfectants had low alkaline phosphatase activities throughout ITS treatment due 
to lower TNAP protein expression and the presence of intracellular low-molecular-weight inhibitors. Our results suggest 
that the interplay of ANKH and TNAP activities is tightly regulated. 
INTRODUCTION 
  Inorganic pyrophosphate (PPi) and phosphate (Pi) affect 
mineralization of articular tissues and have a role in bone 
formation. It has long been known that Pi/PPi ratio is a cru-
cial determinant of the type of crystal product formed (hy-
droxyapatite [HA] vs calcium pyrophosphate dihydrate 
[CPPD]) [1,2]. The recessive ank (progressive ankylosis) 
mice have a loss-of-function mutation in the Ank gene that 
codes for a regulator of PPi transport, and are characterized 
by pathologic calcium apatite crystal deposition and eventual 
bony ankylosis of the affected joints [3]. Patients with two 
rare diseases {craniometaphyseal dysplasia (CMD) [4, 5] 
and familial CPPDD [6-10]} have various dominant ANKH 
(human homolog of Ank) mutations. Though it is likely that 
CMD patients have dominant negative ANKH mutations, 
while familial CPPDD patients have gain-of-function ANKH 
mutations [11], the precise mechanisms whereby these 
ANKH mutations lead to disease pathogenesis are not en-
tirely clear. 
  In familial CPPDD, most of the ANKH mutations were 
located at the 5’ end of the transcript, either in the 5’UTR or 
in codons for amino acid 5 or 48. One ANKH mutation 
(E490) was initially identified in a patient with sporadic 
CPPDD. DNA analysis revealed that two unaffected family 
members of this patient had the same heterozygous mutation 
(E490)[6]. Examinations of the functional consequences of 
these  ANKH mutations have thus far been focused on the 
effect of these mutations on extracellular PPi levels and the  
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results remain controversial [6, 9, 12]. Similar to an Ank 
wild-type transgene, a BAC transgene with the M48T muta-
tion rescued the joint phenotype in the Ank null mice. How-
ever, unlike patients with the ANKH M48T mutation, no 
pathological CPPDD was found in any of these Ank null 
mice with the Ank M48T transgene [11]. It remains unclear 
whether this was due to the lack of an appropriate environ-
ment for CPPD crystal formation in mice. 
  In embryonic chick growth plate chondrocytes, Ank 
overexpression led to increased alkaline phosphatase 
(TNAP) expression and activity [13]. It is likely that the 
regulation of TNAP expression and activity by Ank ensures 
that sufficient TNAP activity is available at the outer mem-
brane surface of growth plate chondrocytes to remove PPi, 
which is a potent inhibitor of mineralization [2, 13, 14]. In 
murine cementoblasts, Pi treatment upregulated Ank, ENPP-
1  (ectonucleotide pyrophosphatase-1) and PiT-1 (a Na
+/Pi 
cotransporter) expression, while TNAP expression was 
downregulated, suggesting that Pi regulates genes involved 
in Pi/PPi homeostasis [15]. 
  It is now clear that Ank/ANKH has function(s) additional 
to regulating PPi export. For example, we recently showed 
that ANKH promotes early erythroid differentiation [16]. In 
this study, we asked whether ANKH affects chondrocyte 
differentiation in ATDC5 cells and also assessed the func-
tional consequence of overexpressing mutant ANKH (E4 
90) in ATDC5 cells. 
MATERIALS AND METHODS 
  Cell culture and DNA transfection. ATDC5 cells [17] 
were cultured in DMEM/F12 medium with 5% FBS. ANKH 
cDNAs (wt and E490) were subcloned into pCMV Tag 5A 24    The Open Rheumatology Journal, 2008, Volume 2  Wang et al. 
(Stratagene) in frame with the c-myc tag at the 3’end. All 
constructs were sequenced to ensure no DNA changes during 
the cloning process. ATDC5 cells were transfected with the 
various constructs using FUGENE 6 (Roche) and the trans-
fectants were selected and maintained in G418. To avoid 
clonal bias, populations of stable transfectants (from two 
separate transfections) were used in all experiments. Differ-
entiation of ATDC5 transfectants was induced in culture 
medium with 1% ITS (Sigma) and the cultures were fed with 
ITS containing medium every 2 days. 
 Real-time  RT-PCR. RNAs were prepared using the Tri-
zol method. Oligo-dT primers were used for reverse tran-
scription. Primer sequences are summarized in Table 1. Mul-
tiple dilutions of the RT mix were used for amplification to 
ensure linearity. G3DPH or -actin expression was used for 
normalization. PCR reactions in triplicates were carried out 
for each sample using iQ SYBR mix (BioRad). Melt curves 
were done at the end of each PCR reaction. Relative quanti-
fication of gene expression was carried out using the 2
-Ct 
method [18], and each sample was compared to expression 
of neo-transfectants at D0. At least two different RNA prepa-
rations and four separate experiments were carried out for 
relative quantification of expression of each gene transcript. 
For each gene expression, statistical significance (p-value 
<0.05) among the transfectants was calculated using Two-
Way Analysis of Variance (ANOVA) and pairwise multiple 
comparison procedures (Holm-Sidak method). 
Table 1.  RT-PCR Primer Sequences 
 
Target  Primer Sequences (5’ to 3’) 
Sox9  F: ATCGGTGAACTGAGCAGC GAC 
R: GCCTGCTGCTTCGACATCCA 
Sox5  F: CTCGCTGGAAGCTATGACC 
R: GATGGGGATCTGTGCTTGTT 
Sox6  F: GGATTGGGGAGTACAAGCAA 
R: CATCTGAGGTGATGGTGTGG 
Col21 F:  TTGAGACAGCACGACGTGGAG 
R: AGCCAGGTTGCCATCGCCATA 
Col X  F: AAAGCTTACCCAGCAGTAGG 
R: ACGTACTCAGAGGAGTAGAG 
BSP  F: GCATGCCTACTTTTATCCTC 
R: GTTCTCGTTGTCATAGACTTC 
MMP-13  F:CATTCAGCTATCCTGGCCACCTTC 
R:CATCCACATGGTTGGGAAGTTCTG 
-actin  F: GTGGGCCGCTCTAGGCACCAA 
R: CTCTTTGATGTCACGCACGATTTC 
GADPH  F: GCTGGCATTGCTCTCAATGA 
R: AGGCCCCTCCTGTTATTATG 
 
 Immunoprecipitation  and  immunoblotting. Lysates of 
the transfectants were first immuno-precipitated with an anti-
myc or a rabbit anti-Ank (raised against the last 20 aa of Ank 
and affinity purified) antibody. The immunoprecipitates 
were run on SDS-PAGE, and transferred to Immobilon-P. 
After blocking with 3% BSA (Sigma) in TBST (10mM Tris 
pH 8, 500mM NaCl, 0.1% Tween 20) for 1h, the blots were 
incubated with a goat anti-Ank antibody [19] for 45 min and 
then with horse radish peroxidase (HRP)-conjugated anti-
goat antibody (Jackson) for 30 min. Specific signals were 
detected by chemiluminescence using Supersignal
®  West 
Femto maximum sensitivity substrates (Pierce Biotech) and 
imaging (BioRad). 
  Alkaline phosphatase activity assay. Lysates (contain-
ing 1μg proteins) from each of the transfectants were incu-
bated with 10mM p-NPP (Sigma-Aldrich) in a bicarbonate 
buffer (50mM Na2CO3/NaHCO2, pH 10.2, 1mM MgCl2, 
10μM ZnCl2) at 37
oC for either 2 or 5 min (at the linear part 
of the reaction). 0.2M NaOH was added to stop the reaction 
and OD was measured at 410nM. At least four experiments 
were carried out using different transfectant preparations. 
RESULTS 
  Expression of endogenous Ank versus transfected 
ANKH transcripts and proteins. To mimic the dominant 
mutations found in familial CPPDD cells, we transfected 
ATDC5 cells that express Ank proteins with ANKH-myc 
constructs with either a wt or a E490 mutation. The myc-
tag enables us to differentiate the transfected from the en-
dogenous transcript/protein. To assess the relative expression 
levels of various ANKH-myc transfectants, a primer pair with 
ANKH sequences for the forward primer and myc sequences 
for the reverse primer was used to carry out RT-PCR. After 
normalization to G3DPH expression, the relative expression 
of ANKH E490 was 5x that of ANKH wt- (Fig. 1), while all 
transfectants including the neo controls expressed similar 
levels of endogenous Ank transcripts. As the primer efficien-
cies between these two primer-pairs might be different, the 
relative amount of transfected vs endogenous ANKH/Ank 
transcript in each transfectant is not known. 
 
Fig. (1). Relative expression levels of endogenous ANK and trans-
fected ANKH-myc transcripts in various transfectants (neo, wt and 
E490). Expression of G3DPH was used for normalization. The ANKH E490 Mutation in CPPDD  The Open Rheumatology Journal, 2008, Volume 2    25 
  We next assessed the relative level of expression of 
ANKH-myc  vs Ank proteins in each transfectant. As we 
failed to obtain clean Western blots of the transfectants using 
anti-myc or anti-Ank antibodies, we first immunoprecipi-
tated lysates of the transfectants using anti-myc antibody (to 
immuno-precipitate ANKH-myc proteins) or with a rabbit 
anti-Ank antibody (to immunoprecipitate all Ank/ANKH 
proteins) and probed the Western blots of the immunopre-
cipitates with a goat anti-Ank/ANKH antibodies. As the en-
dogenous Ank protein is smaller than the ANKH-myc pro-
tein, both proteins can be differentiated on SDS-PAGE. As 
expected, the neo controls did not express any ANKH-myc 
proteins (Fig. 2). For ANKH wt- transfectants, the relative 
levels of ANKH-myc transcript expression corresponded to 
the relative ANKH-myc protein expression (Fig. 2, D0). Un-
expectedly, ANKH E490-transfectants only expressed one 
fifth of the predicted level of proteins. We also assessed 
whether ITS induction of ATDC5 led to an increase in en-
dogenous Ank expression. On D23 of ITS induction, all 
transfectants showed approximately 2-fold increase in en-
dogenous Ank proteins. As expected, there were no signifi-
cant changes in the levels of ANKH-myc proteins over time 
in each transfectant (Fig. 2, D23). 
 
Fig. (2). Relative expression levels of endogenous ANK versus 
ANKH-myc proteins in each transfectant in untreated (D0) and D23 
of ITS induction. 
  Does ANKH play a role in chondrocyte differentia-
tion? ANKH-transfectants and the neo-controls were stimu-
lated with ITS for 10, 17 and 23 days (ITS D10, D17, D23). 
At each time point, real-time RT-PCR was carried out to 
assess the relative expression of chondrocyte markers includ-
ing three Sox transcription factors (Sox 9, Sox 5, and Sox 6), 
one early chondrocyte marker (collagen II1 [Col 21]) and 
three hypertrophic chondrocyte markers (bone sialoprotein 
[BSP], collagen X [ColX], and MMP-13). As we found that 
G3DPH expression changes during the course of ITS induc-
tion of the transfectants, normalizations were carried out 
with  -actin expression instead. After normalization, the 
results were expressed as fold-changes relative to the expres-
sion in Day 0 neo transfectants. For each time-point, we also 
determined the ratio of expression (ANKH-transfectant: neo 
controls; listed below each plot at each time-point in Fig. 3). 
For neo-transfectants, 10 days of ITS treatment resulted in a 
6-, 3- and 34-fold increase in Sox 9, Sox 5 and Sox 6 expres-
sion, respectively (Fig. 3, neo). The high levels of expression 
of these three transcripts were maintained throughout the 
remaining course of ITS treatment (D17 and D23 ITS, Fig. 
3, neo). Neo-transfectants treated with ITS for 10 days had a 
54-fold increase in Col 21 expression. As expected, there 
was a 10-fold drop in Col 21 expression when these trans-
fectants were treated with ITS for 23 days. Maximal expres-
sion of all three hypertrophic chondrocyte markers (Col X, 
BSP and MMP-13) was detected in neo-transfectants treated 
with ITS for 17 and 23 days. Thus, the neo-transfectants 
showed all the expected patterns upon ITS treatments, sug-
gesting that these cells behaved correctly. The same markers 
were used to assess whether over-expression of wild-type 
ANKH affects chondrogenesis and hypertrophic differentia-
tion in ATDC5 ANKH wt-transfectants. Without ITS treat-
ments, ANKH wt- transfectants had significantly higher ex-
pression of Sox 6 and Col X (upregulated 7.9- and 7.7-fold 
respectively compared to that of neo-transfectants), suggest-
ing that these transfectants were already more differentiated 
than the neo-controls. Interestingly, compared to the neo-
controls, significantly lower expression of all three hypertro-
phic chondrocyte markers were detected in ANKH wt-
transfectants treated with ITS for 17 and 23 days (Fig. 3). It 
appears that the normal program of chondrocyte differentia-
tion was disrupted by overexpression of wild-type ANKH. 
  Overexpression of ANKH E490- protein in ATDC5 
cells changed the kinetics of the normal program of ITS-
induced chondrocyte differentiation. In view of two re-
ports showing that Col X transcripts expression was induced 
in CH8/ATDC5 cells expressing the ANKH P5L- proteins 
[9, 12], we asked whether our stable transfectants with 
ANKH  E490- mutations had any effects on ITS induced 
ATDC5 differentiation, using the same set of seven different 
chondrocyte markers. Results from quantitative RT-PCR 
showed that in contrast to ANKH wt- transfectants, expres-
sion of six markers in the ANKH E490-transfectants were 
similar to that of the neo-controls without ITS stimulation. 
There was a three-fold less BSP expression in the ANKH 
E490-transfectants. However, compared to ITS treated neo- 
transfectants, the relative expression of Sox 9 and Sox 5 was 
significantly higher in D17 and D23 ITS stimulated ANKH 
E490-transfectants, while that of Sox 6 was significantly 
higher in D23 ITS treated ANKH E490-transfectants (Fig. 
3). Compared to neo-transfectants, the mutant transfectants 
had a 4.6-fold higher levels of Col X expression with D17 
ITS treatments, suggesting that there is a lag in the initial 
phase of chondrocyte differentiation in the ANKH mutant 
transfectants. ANKH E490-transfectants significantly down- 
regulated BSP expression at D23 ITS, though the extent of 
the downregulated BSP expression was significantly lower 
than that of the ANKH wt- transfectants (p<0.001). Dysregu-
lation of MMP-13 expression was most evident in ANKH 
E490-transfectants, especially at D23 ITS (10x downregu-
lated compared to that of neo-controls; Fig. 3). In summary, 
overexpression of ANKH wt proteins in ATDC5 cells pro-
moted higher expression of Sox 6 and Col X in the absence 
of ITS stimulation, and this appears to modulate the normal 
induction of chondrogenesis upon ITS treatment. In contrast, 
it appears that overexpression of ANKH E490- proteins 
delayed the normal program of ITS-induced chondrogenesis 
in ATDC5 cells. 26    The Open Rheumatology Journal, 2008, Volume 2  Wang et al. 
  Differential alkaline phosphatase (ALP) activities in 
ANKH transfectants. It has been shown that ITS induction of 
ATDC5 cells resulted in an increase in ALP activities [17]. As 
expected, the neo-transfectants showed increased ALP activity 
that plateaued after D17 of ITS treatment. This increase in 
ALP activity was due to a correspondingly  increase in  TNAP 
proteins (normalized with the expression of SHP-2 protein; 
Fig. (4A,B)). Similarly, ANKH wt- transfectants had compara-
ble increase in ALP activity upon ITS treatment until D23, 
when the activity dropped below the D0 level (Fig. 4B). The 
   
Fig. (3). Comparison of the kinetics of expression of Sox9, Sox5, Sox6, Col21, ColX, BSP and MMP13 in ANKH wt-transfectants (solid 
lines) vs neo-controls (dotted lines) vs ANKH E490- transfectants (dashed lines) at D0, D10, D17 and D23 of ITS treatment. Expression of 
-actin was used for normalization. Ratio denotes expression in ANKH-transfectants (either wt or E490) over that of neo-controls. Arrow 
bars denote SD (n=4). * p-value <0.001 (Holm-Sidak method of pairwise multiple comparison). The ANKH E490 Mutation in CPPDD  The Open Rheumatology Journal, 2008, Volume 2    27 
low level of ALP activity at D23 ITS was due to less TNAP 
protein expression as shown by Western blotting (normalized 
with the expression of SHP-2 protein; Fig. 4A,B). Unexpect-
edly, ANKH E490-transfectants showed no increase in ALP 
activity throughout the course of ITS induction (Fig. 4B). 
Compared to ITS treated neo- transfectants, ANKH  E490- 
D17 and D23 ITS transfectants showed about 2-fold less 
TNAP proteins; but the ALP activities were even lower than 
predicted by the protein levels (Fig. 4B) .  W e  t h u s  t e s t e d  
whether there were ALP inhibitors in the lysates from the 
ANKH  E490-transfectants by performing mixing experi-
ments. Lysates from the ANKH wt- and E490-transfectants 
were mixed in different ratios and assayed for ALP activity in 
the mixtures that had 1μg of protein in all cases. The ALP 
activity from 1μg of individual transfectant lysate was also 
measured, and from this, we estimated the expected ALP ac-
tivities in the different mixtures. Mixing ANKH wt- with 
lysates from neo- transfectants resulted in the expected ALP 
activities in the mixtures (Fig. 4C). However, mixing lysates 
from ANKH E490- (either D0 or D17 ITS) resulted in inhibi-
tion of ALP activities in a dose-dependent manner, suggesting 
the presence of inhibitors in the ANKH E490- lysates (Fig. 
4D,E). The maximal inhibition observed was 30% (Fig. 4E). 
Less inhibition (~21%) was observed when lysates from 
ANKH E490- D0 transfectants were used as inhibitors (Fig. 
4D). These inhibitors were of low molecular weights as after 
dialysis of the lysates, the inhibitory activities were no longer 
present in these dialysed lysates. They were specifically found 
in  ANKH  E490-transfectants as ATDC5 cells transfected 
with  ANKH constructs bearing other known CPPDD-
associated ANKH mutations did not have these inhibitors (data 
not shown). In summary, in ANKH  E490-transfectants, 
TNAP protein expression was less than that of neo-controls in 
D17 and D23 ITS, and intracellular low molecular weight 
inhibitors of ALP activities were present. 
DISCUSSION 
  In this study, we took advantage of the inducible ATDC5 
cells to examine the effects of overexpressing ANKH-
constructs (wild-type and mutant) on 1. pre-chondrocytes 
(D0 cells); 2. hypertrophic chondrocytes (ITS D23 cells); 
and 3. the kinetics of hypertrophic differentiation (D10/D17 
cells represent the transition from pre- to hypertrophic chon-
drocytes). We showed that there are about 2-fold more en-
dogenous Ank protein in ATDC5 cells treated with ITS for 
23 days (Fig. 1B). Over-expression of ANKH wt- proteins in 
 
Fig. (4). Alkaline phosphatase (ALP) activity in various transfectants. (A) Western blots showing TNAP protein expression. Quantification 
of relative TNAP expression was normalized with SHP-2 expression (also used as a specificity control). (B) Relative ALP activity of various 
transfectants at different time points (D0, D10, D17, and D23) of ITS treatment expressed as fold relative to that of neo-controls at D0. There 
is a statistical significant difference (Two-Way Analysis of Variance p-value <0.001) among the various transfectants and the neo-controls at 
each time point. Arrow bars denote SD (n=4). Relative ALP activity, TNAP protein levels (estimated by Western blot analysis and normal-
ized with the expression of SHP-2), and ALP/TNAP ratio were tabulated. (C,D,E) Mixing experiments showing the presence of inhibitors in 
the lysates from ANKH E490-transfectants. Lysates from ANKH wt- D17 ITS and neo- D0 (C), ANKH wt- D17 ITS and ANKH E490- D0 
ITS (D), and ANKH wt- D17 ITS and ANKH E490- D17 ITS (E) were mixed in different ratios and assayed for ALP activity in the mixtures 
which had 1μg of protein in all cases. The ALP activity from 1μg of individual transfectant lysate was also measured, and from this, the ex-
pected ALP activities in the different mixtures were estimated. Percentage (%) inhibition of each mixture was plotted against different 
amount of inhibitors (arbitrary numbers from 0 to 200). Solid lines showed % inhibition of undialyzed lysate mixtures and dotted lines 
showed % inhibition of dialyzed lysate mixtures. 28    The Open Rheumatology Journal, 2008, Volume 2  Wang et al. 
ATDC5 cells at the pre-chondrocyte stage appears to disturb 
the normal induction of chondrogenesis by ITS. Over-
expression of ANKH E490- proteins appears to delay the 
kinetics of ITS induced chondrogenesis in ATDC5 cells. 
Thus, our results suggested that the levels of Ank in different 
stages of chondrogenesis are tightly regulated and its expres-
sion level possibly might even dictate the differentiation 
status of chondrocytes. In ank/ank mice which show a loss-
of-function of Ank activities, embryonic and neonatal devel-
opment of chondrocytes appear to be normal. This might 
argue against our results implicating that Ank plays a role in 
embryonic and neonatal chondrocyte development. How-
ever, one cannot rule out the possibility that some proteins 
(such as ENPP-1) might compensate for Ank function early 
in development. It remains unclear whether the altered kinet-
ics of hypertrophic differentiation has any relevance to the 
development of CPPDD. 
 Our  ATDC5  ANKH  E490-transfectants consistently 
expressed more ANKH-myc transcripts than ANKH-myc 
proteins. The reason for the discrepancy between mutant 
mRNA and protein expression is not entirely clear. It might 
be due to lability of the mutant protein. In contrast to our 
results, Williams’ group has recently shown that over-
expression of wt Ank protein in ATDC5 cells had a 4.5-fold 
increase in Col 101 expression at ITS D28 [11]. The rea-
son(s) for this discrepancy is not clear, but could be due to 
the single time point chosen for analysis of Col 101 expres-
sion. In situations where gain-of-function mutations are sub-
jected to feedback transcriptional down-regulation, the out-
come measured from cell culture systems will depend on the 
delicate balance between the gain-of function conferred by 
the mutation and the intrinsic compensatory dampening of 
the response, leading to inconsistent and even contradictory 
results from different laboratories. We found that ITS stimu-
lated the upregulation of endogenous ANK, but not the trans-
fected ANKH (wt or mutant; Fig. 2). Thus, the ratio of the 
endogenous vs transfected forms changed during the course 
of hypertrophic differentiation of the ATDC5 transfectants. 
This might lead to a milder phenotype than expected at ITS 
D17 and D23 in our results. 
  Our results, similar to others, also suggested that there is 
a tight relationship between Ank and TNAP. In hypertrophic 
transfectants, overexpression of ANKH-wt proteins led to a 
downregulation of ALP activity, presumably to maintain a 
balanced [Pi]/[PPi] ratio. In the ANKH E490-transfectants, 
there was an abnormal down-regulation of TNAP expression 
throughout the course of ITS induction. The [Pi]/[PPi] ratio 
dictates the type of calcium crystals formed; hydroxyapatite 
(HA) crystals are formed when the ratiois >100 and CPPD 
crystal formation are promoted when the ratio is <3 [1]. Al-
kaline phosphatase is a key player in CPPDD, as the pres-
ence of TNAP in articular cartilage facilitates both formation 
and dissolution of CPPD crystals [20]. In hypertrophic 
ATDC5 cells, over-expression of ANKH wt- proteins led to 
a decrease in TNAP protein (2-fold less than neo-controls at 
D23 ITS) and ALP activity (4-fold less than neo-controls at 
D23 ITS). If the TNAP level in the extracellular matrix 
(ECM) is limiting, this could lead to less PPi being degraded 
by TNAP, favoring the formation of CPPD crystals. For the 
ANKH  E490-transfectants, we showed that not only less 
TNAP proteins than in neo-controls were detected, but also 
that dialyzable low-molecular-weight inhibitors of ALP were 
present. The identity of the inhibitor(s) has not been defined, 
though our preliminary results indicated that the inhibitor 
was not Pi [21]. We recently showed that endogenous inhibi-
tors such as cysteine might interfere with TNAP’s ability to 
regulate CPPD crystal formation and dissolution [22], 
though it is not clear whether cysteine is the inhibitor in the 
ANKH E490- transfectants. 
  It is likely that the biochemical heterogeneity observed in 
our study might explain the clinical heterogeneity in the fa-
milial CPPDD caused by the different ANKH mutations. The 
British patient, initially thought to have spontaneous CPP 
DD, has the ANKH E490 mutation. CPPDD in this patient 
was late-onset, polyarticular with structural arthropathy of 
both knees. Two other family members also have this het-
erozygous mutation, but with no clinical symptoms of CPP 
DD. However, one of them had bilateral total knee replace-
ment surgery for “osteoarthritis” [6], but the other was nor-
mal at the age of 42. It is possible that other contributing 
factor(s) might be required in addition to the ANKH E490 
mutation, before CPPDD will develop. Similar to the finding 
in ANK deficient mice bearing an ANKH M48T transgene 
[11], results from our studies using the ATDC5 transfectants 
also did not show any evidence that the ANKH E490 muta-
tion is an activating mutation. 
Table 2.  Significant Changes in Markers Expressed in Various ANKH-Transfectants Relative to that of the neo-Controls at Each 
Time-Point 
 
Transfectant ITS  Sox9 Sox5 Sox6  Col21 ColX  BSP MMP-13  ALP Activity  TNAP Protein 
ANKH-wt  D0   1.4x  7.9x  5x  7.7x        
 D10    1.7x  2x  33x   10x  2.5x    
 D17     33x  2.5x   3.3x    
 D23    1.6x  2x   10x  33x  2.5x  4x  2x 
                 
ANKH- E490  D0        3.3x      
 D10      50x  10x  2.5x  3.3x  2.8x  
 D17  9.6x  1.9x    4.6x  3.3x   5x  2x 
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  Based on our results in this study, we hypothesize that 
CPPDD-associated ANKH proteins lead to dysregulation of 
modulators of Pi/PPi homeostasis such as TNAP. As Pi/PPi 
homeostasis is a dynamic process and probably subject to 
feedback mechanisms, it would be very difficult to replicate 
pathological [Pi]/[PPi] conditions in in vitro culture systems, 
leading to the generation of inconsistent and contradictory 
results. The long-time observation that both HA and CPPD 
crystals were found in CPPDD patients has been puzzling. It 
is likely that in these patients, the dynamic interplay of 
ANKH and TNAP led to the fluctuating local [Pi]/[PPi] ra-
tio, resulting in the formation in the joints of either HA 
(when e[Pi]/e[PPi] ratio is >100) or CPPD crystals (when 
e[Pi]/e[PPi] is <3). Flare-ups of CPPDD probably occur in 
situations where the negative feedback loop is not optimal. 
 ANKH mutations have only been detected in rare families 
with CPPDD and one ANKH SNP was associated with spo-
radic cases in UK [9]. In one CPPDD family from New Eng-
land, the disease was linked to a locus on chromosome 8q 
instead of chromosome 5p where ANKH is mapped [23]. A 
recent study suggested that ENPP-1 and TNAP are not major 
determinants of sporadic CPPDD susceptibility [24]. ANKH 
transcripts were upregulated in cartilage from four CPPDD 
patients [25]. Thus, one cannot rule out that dysregulation of 
ANKH and TNAP by factors such as cytokines might be 
important in the manifestation of sporadic CPPDD. 
CONCLUSIONS 
  In summary, we propose the following model for the 
development of CPPDD: under normal conditions, the inter-
play of ANKH and TNAP facilitates normal mineralization. 
Dysregulation of ANKH (either by mutation or induced by 
cytokines) lead to a dysregulation of TNAP. Together with 
other yet-to-be-identified factors, pathological mineralization 
ensued, leading to CPPDD disease expression. 
ABBREVIATIONS 
ALP =  Alkaline  phosphatase 
ANK =  Progressive  ankylosis 
ANKH  =  Human homolog of progressive ankylosis 
ANOVA  =  Two-way analysis of variance 
BAC =  Bacterial  artificial  chromosome 
BSP =  Bone  sialoprotein 
BSA  =  Bovine serum albumin 
CMD =  Craniometaphyseal  dysplasia 
Col 21 =  Collagen  II  1 
Col X  =  Collagen X 
CPPDD  =  Calcium pyrophosphate dihydrate crystal  
     deposition disease 
ECM =  Extracellular  matrix 
ENPP-1 =  Ectonucleotide  pyrophosphatase-1 
FBS  =  Fetal bovine serum 
MMP13  =  Matrix metalloproteinase 13 
ITS  =  Insulin, transferring, selenium 
TNAP  =  Tissue non-specific alkaline phosphatase 
Pi =  Inorganic  phosphate 
p-NPP =  Para-nitrophenyl  phosphate 
PPi =  Inorganic  pyrophosphate 
UTR =  Untranslated  region 
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